Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_assertion description "[The use of mutations of the KRAS codons 12 and 13 as a selection biomarker for anti-endothelial growth factor receptor (EGFR) monoclonal antibody treatment is at present the first major step towards individualised treatment for patients with metastatic colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_assertion evidence source_evidence_literature NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_assertion SIO_000772 21289333 NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_assertion wasDerivedFrom befree-2016 NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_assertion wasGeneratedBy ECO_0000203 NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.
- befree-2016 importedOn "2016-02-19" NP869871.RAKblwGOfYgqp7-7RGrgHiWzPkx9e1ayNW3iDxE8m-eQA130_provenance.